Spyre Therapeutics, Inc. (SYRE)

36.72 +1.53 (+4.33%) As of 12:13PM EDT. Market open.

Spyre Therapeutics, Inc.

221 Crescent Street
Building 23 Suite 105
Waltham, MA 02453
United States
617 651 5940
https://www.spyre.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 30

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Cameron Turtle DPHIL, Ph.D.	CEO & Director	674.17k	N/A	1990
Mr. Scott L. Burrows	Chief Financial Officer	331.81k	N/A	1977
Ms. Heidy Abreu King-Jones J.D., L.L.M.	Chief Legal Officer & Corporate Secretary	568.87k	N/A	1983
Dr. Janet Gunzner-Toste M.B.A., Ph.D.	Senior Vice President of Operations	N/A	N/A	N/A
Mr. Brian Connolly	Chief Technical Officer	N/A	N/A	N/A
Mr. Eric McIntyre	Vice President of Finance & Investor Relations	N/A	N/A	N/A
Mr. James Myers	Vice President of Quality & Compliance	N/A	N/A	N/A
Dr. Kelly Boothe Ph.D.	Senior Director of Corporate Communications & Investor Relations	N/A	N/A	N/A
Dr. Justin LaFountaine Ph.D.	Senior Vice President of Corporate Development	N/A	N/A	N/A
Ms. Melissa Cooper	Senior Vice President of People	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Corporate governance

Spyre Therapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.